9 GHP Biotechnology & Lifesciences Awards 2025 triving to forever revolutionise biotech product launches using fractional medical affairs , BioLogic is transforming the way companies in this space work and empowering them through a flexible, project-based model of engagement . By eradicating the need for expensive and risky full-time equivalent (FTE) methods, the process of launching new projects is made faster, more efficient, and less expensive in the long run with the consulting services offered by the firm resulting in tailored support grounded in expertise . The bespoke approach adopted by BioLogic leads not only to the acceleration of a client’s clinical development, but also aids in enhancing strategy and reshaping of the dynamics in the market around their client companies . As Mary Hames, the firm’s CEO, explains: “BioLogic ensures our clients achieve their goals with efficiency and impact. Combining innovation with deep industry expertise, we strengthen physician relationships and guide clients through the complexities of the biopharma landscape.” As for some examples of the stellar work that the firm has done, a taste of completed projects includes outreach and feasibility efforts for a client approaching Phase 3 of clinical trial with more than 50 institutions registering their interest for a trial involving a rare disease. Moreover, in order to enhance recruitment during these Phase 3 trails, the team have developed and launched an informative and intuitive patient-facing website. Initiatives such as these are simply the tip of the spear, however. One of the most exciting ventures the team have worked on in recent months has been a full evaluation of US commercial diagnostic laboratories involving the identification of gaps in genetic diagnostic capabilities across the clients’ main areas of focus. At time of writing, these findings are just a few days removed from being presented in poster format at a variety of prominent congresses across the country. Despite leading the charge in this sector, it is not always plain sailing for BioLogic, which navigates the challenges that arise from working with companies that are locked in a cycle of continuous change. With the regulatory environment evolving as much as those within it, the degree of difficulty is compounded. Thus, Mary told us: “Part of our value is helping these companies with a scalable, flexible solution during these difficult times.” When it comes to traversing a landscape fraught with pitfalls, BioLogic succeeds by ensuring that its work closely follows EMA and FDA regulations, as well as by attending talks and meetings Headquartered in Grand Haven, Michigan, BioLogic Pharma Solutions is quickly rising up the ranks to become one of the premier fractional medical affairs consulting firms in the pharmaceuticalandbiotechindustries.Withafocusonclinicalstrategy,development,and trial execution, it is the team’s wide range of specialisations – including various medical affairs core capabilities, clinical development , and genetic diagnostics optimisation – that sets them apart and enables superior product launches. We were able to catch up with CEO Dr. Mary Hames to find out more. Best Emerging BioTech & Pharmaceutical Consulting Firm 2025 – USA & GHP Client Service Excellence Award 2025 on the leading edge of industry trends and regulatory shifts. The unique fractional medical affairs support model also plays a big part in the firm’s success, as it sees the team become an extension of the client’s operation, leading to seamless integration and strategic alignment at every turn. When it comes to BioLogic’s internal culture, working in a united fashion towards common goals are prioritized in parallel with individual well-being and growth. Building the ‘Dream Team’ involves recruiting proven talent and providing opportunities for proactive development, values at the very heart of the firm. This unwavering commitment to its team has resulted in BioLogic experiencing significant growth over the past couple of years, with its staff becoming knowledgeable on the current trends defining this market, such as AI, diagnostics, KOL engagement, and more. For Mary: “We believe our strong team and culture are a competitive advantage in our industry, as happy, engaged workers frankly do better work.” Having spent the final quarter of last year honing its scalability processes and developing several innovative technologies in the fields of congress execution and medical information handling, BioLogic Pharma Solutions is excited to be working towards a future of welcoming new customers into the fold and continuing to scale its growth. We wish Mary and the team at this multiaward-winning firm all the best as they work towards these aims. Contact: Mary Hames Company: BioLogic Pharma Solutions Web Address: https://biologicpharmasolutions.com/ S AIS-Mar25010 BioLogicPharmaSolutions
RkJQdWJsaXNoZXIy NTY1MjM3